WANG Miao, LIU Hong-xia, WANG Ling-hong, LIU Hui-juan
Objective: To investigate the effects of recombinant human growth hormone (rhGH) combined with letrozole (LE) on growth and hormone levels in boys with large bone age and adolescent short stature. Methods: A prospective study was conducted on 43 boys with large bone age and adolescent short stature who were treated at our hospital from July 2022 to September 2024. All subjects received rhGH combined with LE therapy. Before treatment and at 1, 6, 12, and 18 months of treatment, the following parameters were measured: height standard deviation scores [height standard deviation score for chronological age (HtSDS-CA) and height standard deviation score for bone age (HtSDS-BA)], sex hormones [luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), testosterone (T)], physical indicators [body mass index (BMI)], routine blood parameters [hemoglobin (HGB), red blood cell count (RBC), white blood cell count (WBC), platelet count (PLT)], growth factors [insulin-like growth factor-1 (IGF-1)], and biochemical parameters [urea, alkaline phosphatase (ALP)]. Adverse reactions were also recorded. Results: After 1, 6, 12, and 18 months of treatment, HtSDS-CA, HtSDS-BA, LH, FSH, T, BMI, HGB, RBC, and IGF-1 levels were significantly higher than those before treatment (P<0.05). No statistically significant differences were observed in WBC, PLT, or ALP compared with pretreatment levels (P>0.05). E2 levels were below the lower detection limit. After 6 and 12 months of treatment, urea levels were higher than those before treatment (P<0.05). Adverse reactions mainly included elevated gonadotropin and T levels, abnormal blood glucose, elevated total bilirubin and uric acid, thyroid dysfunction, and skin problems. Conclusion: rhGH combined with LE can effectively promote growth and development and improve hormone levels in boys with large bone age and adolescent short stature. The adverse reactions are transient and resolve after drug discontinuation.